Here is what the page “Life Biosciences Reports Early Safety Data for Cellular Reprogramming Glaucoma Drug” contains. Life Biosciences announced that three glaucoma patients have received a single injection of its experimental cellular reprogramming therapy, with no serious adverse events reported to date. The Boston-based biotech is developing the drug as a potential one-time treatment that could reverse damage to the optic nerve by reprogramming cells to a younger state. The update, shared yesterday, marks an early but important step in clinical testing, as the company moves from preclinical promise to human safety data.
Glaucoma is a leading cause of irreversible blindness worldwide, affecting millions, and current treatments only slow progression rather than restore vision. Life Biosciences is among a handful of companies pursuing cellular reprogramming—a field that has drawn attention from investors and researchers for its potential to treat age-related diseases. This listing links straight to the original page, where the content is available in full.